MedTrace Logo

High Dose BAYA1040_Nifedipine: a Long Term Combination Study

NCT01294215 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2014-06-23

No results posted yet for this study

Summary

This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040\_Nifedipine 80 mg/day (40 mg twice daily) with other antihypertensives in patients with essential hypertension who are not at target blood pressure by the combination of BAYA1040\_Nifedipine 40 mg once daily and other antihypertensives.

Conditions

Interventions

DRUG

Nifedipine (Adalat, BAYA1040)

Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-11-30
Completion
2012-06-30

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01294215 on ClinicalTrials.gov